Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Moxetumomab pasudotox-tdfk |
Trade Name | Lumoxiti |
Synonyms | CAT-8015 |
Drug Descriptions |
Lumoxiti (moxetumomab pasudotox-tdfk) is an immunotoxin targeting CD22-positive tumor cells (PMID: 30030507). Lumoxiti (moxetumomab pasudotox-tdfk) is FDA approved for use in patients with relapsed or refractory hairy cell leukemia (FDA.gov). |
DrugClasses | CD22 Immune Cell Therapy 15 |
CAS Registry Number | 1020748-57-5 |
NCIT ID | C68819 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Moxetumomab pasudotox-tdfk | Moxetumomab pasudotox-tdfk | 0 | 0 |
Moxetumomab pasudotox-tdfk + Rituximab | Moxetumomab pasudotox-tdfk Rituximab | 0 | 1 |